saralasin
Sign in to saveSaralasin is a competitive angiotensin II receptor antagonist with partial agonistic activity. The aminopeptide sequence for saralasin differs from angiotensin II at three sites: At position 1, sarcosine replaces aspartic acid, thereby increasing the affinity for vascular smooth muscle AT II receptors and making sara resistant to degradation by aminopeptidases. At position 5, isoleucine is replaced by valine At position 8, phenylalanine is replaced by alanine which leads to a smaller stimulatory effect. Saralasin was used to distinguish renovascular hypertension from essential hypertension
Research
1,869 papers- Preclinical pharmacology of saralasin.Kidney international. Supplement · 1979
- [The saralasin test in clinical evaluation of hypertensive states].Bollettino della Societa italiana di cardiologia · 1978
- Physiologic studies with saralasin in animals.Kidney international. Supplement · 1979
- Saralasin-induced renin release: its blockade by prostaglandin synthesis inhibitors in the conscious rat.Hypertension (Dallas, Tex. : 1979) · 1979
- Angiotensin as a renal, adrenal, and cardiovascular hormone: responses to saralasin in normal man and in essential and secondary hypertension.Kidney international. Supplement · 1979
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 911.498
Show 4 more facts
- chemical formula
- C₄₂H₆₅N₁₃O₁₀
- canonical SMILES
- CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)C)C(=O)NC(CC2=CN=CN2)C(=O)N3CCCC3C(=O)NC(C)C(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)CNC
- isomeric SMILES
- C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
- subject has role
- angiotensin II receptor antagonist
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- External links
Saralasin is a competitive angiotensin II receptor antagonist with partial agonistic activity. The aminopeptide sequence for saralasin differs from angiotensin II at three sites: At position 1, sarcosine replaces aspartic acid, thereby increasing the affinity for vascular smooth muscle AT II receptors and making sara resistant to degradation by aminopeptidases. At position 5, isoleucine is replaced by valine At position 8, phenylalanine is replaced by alanine which leads to a smaller stimulatory effect. Saralasin was used to distinguish renovascular hypertension from essential hypertension before its discontinuation in January 1984 because of many false-positive and false-negative reports.
==References==
Excerpted from Wikipedia’s “saralasin” article, available under the CC BY-SA 4.0 licence.